Genetic Prognostic Index Influences Patient Outcome for Node-Positive Breast Cancer

Asaka, Shinichi; Fujimoto, Takashi; Akaishi, Junko; Ogawa, Kenji; Onda, Masamitsu

doi:10.1007/s00595-006-3261-2

Cited by 24 publications

(27 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in this study, only implicated in soft tissue sarcomas, leukemia, astrocytoma and in cancers of the breast, prostate, lung, liver and esophagus. [2][3][4][5][6][7][8][9][10] Decreased expression of LATS2 is seen in prostate cancer tissues, 7 and levels of phosphorylated LATS1/LATS2 are reduced in tumor susceptible mst1/2 liver-specific knockout mice. 9 Classically, tumor suppressor loss-of-function occurs through mutations.…”

Section: Role Of Lats As Tumor Suppressormentioning

confidence: 99%

“…As such, loss of either of these genes leads to malignant phenotypes. [2][3][4][5][6][7][8][9][10] Therefore, understanding how LATS1 and LATS2 operate is key to understanding tumorigenesis. This review will explore what we know about how these tumor suppressors function, both as individual proteins and collectively, highlighting their potential redundant or distinct roles.…”

Section: A New Governor Of Cellular Homeostasismentioning

confidence: 99%

“…68 A following study showed that LATS1, along with four other genes, were underexpressed in node-positive breast tumors and together could serve as prognostic factors for breast cancer. 4 LATS can also provide details about how a patient is likely to respond to a given treatment. In one study, patients with low LATS2 expression were significantly more likely to respond positively to etoposide plus cyclophosphamide (EC) treatment, whereas low levels of LATS1 were also associated, but not significantly, with better response rates to EC treatment.…”

Section: Cip1mentioning

confidence: 99%

See 2 more Smart Citations

LATS tumor suppressor: A new governor of cellular homeostasis

Visser

Yang²

2010

Cell Cycle

182

197

View full text Add to dashboard Cite

Section: Role Of Lats As Tumor Suppressormentioning

confidence: 99%

Section: A New Governor Of Cellular Homeostasismentioning

confidence: 99%

Section: Cip1mentioning

confidence: 99%

See 1 more Smart Citation

LATS tumor suppressor: A new governor of cellular homeostasis

Visser

Yang²

2010

Cell Cycle

182

197

View full text Add to dashboard Cite

“…Because the stomach is also of foregut origin, the high frequency of LOH at the IRX1 locus in gastric cancer suggested that the IRX1 gene may be involved in the development of gastric cancer. Asaka et al (2006) reported that IRX3 is downregulated in breast cancer patients with shorter survival times. IRX3 was also downregulated in androgen-insensitive prostate cancer cell lines (Zhao et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma

et al. 2010

View full text Add to dashboard Cite

The IRX1 tumor suppressor gene is located on 5p15.33, a cancer susceptibility locus. Loss of heterozygosity of 5p15.33 in gastric cancer was identified in our previous work. In this study, we analyzed the molecular features and function of IRX1. We found that IRX1 expression was lost or reduced in gastric cancer. However, no mutations were identified in IRX1-encoding regions. IRX1 transcription was suppressed by hypermethylation, and the expression of IRX1 mRNA was partially restored in gastric cancer cells after 5-Aza-dC treatment. Restoring IRX1 expression in SGC-7901 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. We identified a number of target genes by global microarray analysis after IRX1 transfection combined with real-time PCR and chromatin immunoprecipitation assay. BDKRB2, an angiogenesis-related gene, HIST2H2BE and FGF7, cell proliferation and invasionrelated genes, were identified as direct IRX1 target genes. The hypermethylation of IRX1 was not only detected in primary gastric cancer tissues but also in the peripheral blood of gastric cancer patients, suggesting IRX1 could potentially serve as a biomarker for gastric cancer.

show abstract

“…Knockdown of LASP1 in the breast cancer cell lines BT-20 and MCF-7, and the ovarian cancer cell line SKOV-3 has however been demonstrated to result in strong inhibition of proliferation and migration (13,14). In 2006, LASP1 was identified as one of 5 genes down-regulated in poor prognosis, lymph-node-positive breast cancer (15). LASP1 has also been identified as a potential p53 (a tumour suppressor) target in hepatocellular carcinoma, with further work suggesting that p53 may play a role in influencing tumour metastasis through LASP1 (16).…”

Section: Introductionmentioning

confidence: 99%

Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer

et al. 2012

View full text Add to dashboard Cite

Abstract. HER2/neu is associated with poorer clinical outcome in breast cancer. Expression patterns of co-localised cancerassociated genes at 17q12-21 were examined using RT-PCR. The study group consisted of a 96-patient cohort. Relative quantity of mRNA expression was calculated using the comparative cycle threshold method and Qbase software. Results were analysed to detect expression patterns among the genes, and to identify associations between expression levels and clinical data. Levels of HER2/neu correlated with those of GRB7 (r=0.551, p<0.001), RARA (r=0.391, p<0.001), RPL19 (r=0.549, p<0.001) and LASP1 (r=0.399, p<0.001). GRB7 was significantly inversely associated with improved DFS at 60 months (p=0.036). RARA levels were greater in HER2/neu-positive as opposed to HER2/ neu-negative patients (p= 0.021); levels were significantly higher in ER-positive patients, relative to those who were ER-negative (p=0.003). Levels of RPL19 were significantly higher in the HER2/neu-overexpressing (p=0.010) and luminal B subtypes (p=0.007). LASP1 levels were higher in those patients who had been classified clinically as HER2/neu-positive (p=0.004). This study reaffirms the correlation between HER2/neu and the co-localised LASP1 and GRB7; the latter target may hold additional significance in addition to being a surrogate marker for HER2/neu expression. The relationship identified between RARA and ER-positivity may herald an avenue for targeted therapy of these tumours.

show abstract

Genetic Prognostic Index Influences Patient Outcome for Node-Positive Breast Cancer

Abstract: These five genes might play an important role in deciding the behavior of node-positive breast cancer. The PI system could thus predict the prognosis of node-positive breast cancer, and might therefore be able to provide valuable information for the prognosis of breast cancer patients.

Cited by 24 publications

References 47 publications

LATS tumor suppressor: A new governor of cellular homeostasis

LATS tumor suppressor: A new governor of cellular homeostasis

Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma

Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer

Contact Info

Product

Resources

About